

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION N	IO. I	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/048,086		03/05/2002	Jorg Tillack	Mo-6924/LeA 33,697	1660
157	7590	04/20/2004		EXAMI	NER
	POLYMEI	RS LLC	SELLERS, ROBERT E		
100 BAYER ROAD PITTSBURGH, PA 15205				ART UNIT	PAPER NUMBER
1111550	, , , , , , , , , , , , , , , , , , ,	13203		1712	

DATE MAILED: 04/20/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/048,086	TILLACK ET AL.
Office Action Summary	Examiner	Art Unit
•	Robert Sellers	1712
The MAILING DATE of this communication appeariod for Reply		
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.  after SIX (6) MONTHS from the mailing date of this communication.  If the period for reply specified above is less than thirty (30) days, a rep  If NO period for reply is specified above, the maximum statutory period  Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a ly within the statutory minimum of thi will apply and will expire SIX (6) MOI a cause the application to become A	reply be timely filed  rty (30) days will be considered timely.  NTHS from the mailing date of this communication.  BANDONED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on 09 A	<u>April 2004</u> .	
20/21	s action is non-final.	
3) Since this application is in condition for allowa		
closed in accordance with the practice under	Ex parte Quayle, 1935 C.	D. 11, 453 O.G. 213.
Disposition of Claims		
4) ☐ Claim(s) 1-32 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-32 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/	awn from consideration.	
Application Papers		
9)☐ The specification is objected to by the Examin	ner.	
10)☐ The drawing(s) filed on is/are: a)☐ ac	cepted or b) objected to	by the Examiner.
Applicant may not request that any objection to the	e drawing(s) be held in abey	ance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the corre	ction is required it the drawir Examiner. Note the attach	ed Office Action or form PTO-152.
Priority under 35 U.S.C. § 119	•	
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document copies of the priority document copies of the certified copies of the priority document copies of the certified copies of the priority document copies of the certified copies of the priority document copies of the certified copies of the priority document copies of the certified copies of the priority document copies of the priority document copies of the certified copies of the priority document copies.  * See the attached detailed Office action for a list	nts have been received.  nts have been received in  iority documents have been  au (PCT Rule 17.2(a)).	Application No en received in this National Stage
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date	Paper N	w Summary (PTO-413) lo(s)/Mail Date of Informal Patent Application (PTO-152)

Application/Control Number: 10/048,086

Art Unit: 1712

The text of section 103(a) of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 1-32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Schmalstieg et al. Patent No. 6,060,574 in view of Groegler et al. Patent No. 4,001,232.

The rejection is maintained for the reasons of record set forth in the previous Office action. The arguments filed April 9, 2004 have been considered and are unpersuasive.

1. Schmalstieg et al. in column 5, lines 26-31 states:

"Examples of suitable amidines in which the CN double bond is a constituent of a cyclic system include 2-methyltetra-hydropyrimidines which are substituted in the 1-position. They can be obtained in accordance as described in DE-A 2,439,550 by reacting N-monosubstituted 1,3-propane diamines with acetoacetic acid derivatives."

- 2. DE-A 2,439,550 is the priority application for Groegler et al. (cover page, "Foreign Application Priority Data" section). Groegler et al. shows the preparation of 2,3-dimethyl-3,4,5,6-tetrahydropyrimidine in Example 2 (col. 7, line 5), Example 12 (col. 7, lines 58-59) and Example 13 (col. 7, line 67).
- 3. The primary reference to Schmalstieg et al. specifically refers to Groegler et al. which does not provide a laundry list as evidenced by the numerous examples of the claimed species. The suggestion or motivation to employ the 2,3-dimethyl-3,4,5,6-tetrahydropyrimidine of Groegler et al. as the particularly preferred alkyl-substituted amidine catalyst of Schmalsteig et al. (col. 5, lines 15-17) resides in the aforementioned section of Schmalsteig et al.

Application/Control Number: 10/048,086

Art Unit: 1712

There is a reasonable expectation of success that the use of the 2,3-dimethyl-3,4,5,6-tetrahydropyrimidine of Groegler et al. as the alkyl-substituted amidine catalyst of Schmalsteig et al. reduces the reaction temperature and/or time. The combined disclosures of Schmalstieg et al. in view of Groegler et al. teaches or suggests all of the claimed limitations. Thus, a *prima facie* case of obviousness has been established in accordance with MPEP § 2142 quoting *In re Vaeck* (20 USPQ2d 1438, Federal Circuit 1991).

Claims 1-32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lauman Patent No. 4,753,826 and Xiao et al. Patent No. 6,153,709 in view of (Schmalsteig et al. and Boutillier et al. Patent No. 4,908,408) and (Japanese Patent No. 50-117771 and Tarbutton et al. Patent No. 6,486,256).

The rejection is maintained for the reasons of record set forth in the previous Office action. The arguments filed April 9, 2004 have been considered and are unpersuasive.

4. Tarbutton et al. in column 3, lines 8-11 indicates that "[w]e have surprisingly found that a combination of two different amidine catalyst species, in particular cyclic amidine catalysts, can provide enhanced adhesive properties." The claimed species of 1,2-dimethyl-1,4,5,6-tetrahydropyrimidine is named in column 9, lines 9-10 (equivalent to 2,3-dimethyl-3,4,5,6-tetrahydropyrimidine according to Chemical abstracts registry no. 4271-96-9) and exhibited in column 24, Table 4, Example Catalyst 42.

Application/Control Number: 10/048,086

Art Unit: 1712

- 5. The Japanese patent particularly designates
- 1,2-dimethyl-1,4,5,6-tetrahydropyrimidine as a catalyst for the reaction of an epoxy resin and a diisocyanate.
- 6. The 1,2-dimethyl-1,4,5,6-tetrahydropyrimidine of Tarbutton et al. and the Japanese patent is not part of a laundry list, but is specifically named. The suggestion or motivation to utilize the 1,2-dimethyl-1,4,5,6-tetrahydropyrimidine of Tarbutton et al. and the Japanese patent as the catalyst of Lauman and Xiao et al. is to enhance the adhesive properties (Tarbutton et al., col. 3, lines 8-11), sustain load durability and impact resistance over a wide temperature range, and facilitate epoxy copolymerization with an amine (Tarbutton et al., col. 9, lines 11-20). The Japanese patent confirms the operability of 1,2-dimethyl-1,4,5,6-tetrahydropyrimidine in catalyzing the reaction between an epoxy resin and diisocyanate.
- 7. There is a reasonable expectation of success that the use of the 1,2-dimethyl-1,4,5,6-tetrahydropyrimidine of Tarbutton et al. and the Japanese patent as the catalyst of Lauman and Xiao et al. facilitates the reaction between the epoxy resin and both amine and isocyanate groups. The combined teachings of Lauman and Xiao et al. in view of the Japanese patent and Tarbutton et al. teaches or suggests the claim limitations regarding the 2,3-dimethyl-1,4,5,6-tetrahydropyrimidine catalyst. Therefore, a *prima facie* case of obviousness has been established in accordance with MPEP § 2142 quoting *In re Vaeck*.

Page 5

Application/Control Number: 10/048,086

Art Unit: 1712

- 8. According to MPEP § 2144 under the heading "RATIONALE DIFFERENT FROM APPLICANT'S IS PERMISSIBLE", "It is not necessary that the prior art suggest the combination to achieve the same advantage or result discovered by applicant (*In re Linter*, 173 USPQ 560, CCPA 1972; and *In re Dillon*, 16 USPQ2d 1897, 1901, "it is not necessary in order to establish a *prima facie* case of obviousness that . . . there be a suggestion in or expectation from the prior art that the claimed compound or composition will have the same or a similar utility as one newly discovered by applicant.").
- 9. The motivation of employing the 1,2-dimethyl-1,4,5,6-tetrahydropyrimidine of the Japanese patent and Tarbutton et al. as the catalyst of Lauman and Xiao et al. to impart adhesive properties, sustain load durability and enhance the epoxy-amine and epoxy-isocyanate reactions is permissible even if it does not conform to the alleged motivations.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

(571) 272-1093 (Fax no. (703) 872-9306) Monday to Friday from 9:30 to 6:00 EST

Any administrative inquiries can be obtained by accessing the Patent Application Information Retrieval (PAIR) system. Published applications are available through either private or public PAIR. Unpublished applications are available via private PAIR only. Consult <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a> or contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free).

Robert Sellers Primary Examiner Art Unit 1712

rs 4/16/04